DOD Biotech PCL Goodwill
The Goodwill of DOD Biotech PCL (DOD.BK) as of Aug 10, 2026 is 252,359.00 THB. In the previous year, Goodwill was 252,359.00 THB — a change of 0.00% (lower).
Get this data via API
Financial Data API
Goodwill
252,359.00THB
YoY
0.00%
Last updated:
Goodwill of DOD Biotech PCL is 2026 252,359.00 THB. Goodwill of DOD Biotech PCL was 2025 252,359.00 THB. It decreases by 0.00% lower compared to the previous year.
Access this data via the Eulerpool API
DOD Biotech PCL Stock analysis
What does DOD Biotech PCL do? DOD Biotech PCL is a Thai biotechnology company specializing in the production of pharmaceuticals, diagnostics, and research products. Established in 2004, the company has become one of the most reputable biotechnology companies in Thailand. Its business model is based on the development and manufacturing of products used in medicine, veterinary medicine, and research. DOD Biotech PLC focuses on continually evolving and adapting its products to meet customer needs. Its main areas of focus are the production of pharmaceuticals, particularly anti-cancer drugs, diabetes medications, cardiovascular medications, and infection treatments. Additionally, the company manufactures diagnostics for disease early detection and precise diagnosis. It also offers a variety of products for research purposes. DOD Biotech PCL has partnerships with several companies in other countries, particularly in Asia and Europe. Its largest partner is the Indian company Sun Pharma, with which it has had a successful collaboration for many years. The company is known for its high-quality standards and is certified to ISO 9001:2015 and follows the Good Manufacturing Practices (GMP) required by the Thai FDA. DOD Biotech PCL has received international recognition, including the Frost & Sullivan Thailand Excellence Award and being recognized as a top 30 company in Thailand in 2020. Over the years, the company has built a loyal customer base that appreciates its high-quality products and excellent customer service. It has a strong online presence to better reach and serve its customers. In summary, DOD Biotech PCL is a leading biotechnology company in Thailand with a wide range of pharmaceuticals, diagnostics, and research products. It has earned an excellent reputation for its high-quality standards and top-notch customer service. With its strong online presence and partnerships with other companies in Asia and Europe, DOD Biotech PCL will undoubtedly remain an important player in the global healthcare market in the future. DOD Biotech PCL is one of the most popular companies on Eulerpool.
Frequently Asked Questions about DOD Biotech PCL stock
Goodwill of DOD Biotech PCL is 252,359.00 THB in 2026.
Goodwill of DOD Biotech PCL changed from 252,359.00 THB to 252,359.00 THB, representing a 0.00% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Goodwill DOD Biotech PCL since 2006 – with annual values, charts, and detailed analysis.
Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.
Goodwill's THB is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's DOD Biotech PCL historically and in real time.
Access this data via the Eulerpool API
Balance Sheet — DOD Biotech PCL
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — DOD Biotech PCL
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth